vg-3927 - Search News

Vigil’s TREM2-Targeted Alzheimer’s Treatment Shows Early Promise, Moves On to Phase II

Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially representing a new avenue for treating Alzheimer’s disease.

Business Insider · 3d

Vigil Neuroscience reports data from Phase 1 trial on VG-3927

Vigil Neuroscience (VIGL) announced positive data from its completed Phase 1 clinical trial evaluating VG-3927 for the potential treatment of

Hosted on MSN · 3d

Vigil Neuroscience shares rise on positive Alzheimer's trial data

Shares of Vigil Neuroscience , Inc. (NASDAQ:VIGL) climbed 14% after the company reported favorable results from its Phase 1 clinical trial for VG-3927, a potential treatment for Alzheimer's disease (AD).

Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer’s Disease

Safety, tolerability, pharmacokinetic, and pharmacodynamic profile supports continued development of VG-3927 as potential once-daily oral ...

Nasdaq3d

Vigil Neuroscience Reports Positive Phase 1 Data Supporting Continued Development Of VG-3927

(RTTNews) - Vigil Neuroscience (VIGL) reported positive data from completed Phase 1 clinical trial evaluating VG-3927 for the potential treatment of Alzheimers disease. The company said ...

Vigil Neuroscience's Alzheimer's Candidate Shows Encouraging Safety Profile, Plans To Start Mid-Stage Study In Q3

Vigil Neuroscience's VG-3927 Phase 1 trial shows strong safety, 50% sTREM2 reduction, and potential Alzheimer's treatment; Phase 2 begins Q3 2025.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Trending now